Delving into the Latest Updates on 赛斯尔擎生物技术（上海）有限公司 with Synapse

An Exploratory Clinical Study on the Safety and Efficacy of Autologous Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CG-102-12C) in the Treament of Advanced Hepatocellular Carcinoma

This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-102-12C in the participants with GPC3-positive advanced hepatocellular carcinoma who previously received adequate but uneffective systemic standard treatments.

开始日期2025-06-20

申办/合作机构

浙江大学

[+1]

NCT06999031

/ Recruiting早期临床1期IIT

An Exploratory Clinical Study on the Safety and Efficacy of Autologous T Cell Injection Targeting BCMA Chimeric Antigen Receptor (CG-105-12) in the Treatment of Patients With Relapsed / Refractory Multiple Myeloma

This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-105-12 in the participants with BCMA-positive relapsed/refractory multiple myeloma who previously received adequate but uneffective standard treatments.

开始日期2024-09-05

申办/合作机构

南昌大学第一附属医院

[+1]

100 项与赛斯尔擎生物技术（上海）有限公司相关的临床结果

登录后查看更多信息

0 项与赛斯尔擎生物技术（上海）有限公司相关的专利（医药）

登录后查看更多信息

100 项与赛斯尔擎生物技术（上海）有限公司相关的药物交易

登录后查看更多信息

100 项与赛斯尔擎生物技术（上海）有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年09月11日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

早期临床1期

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Anti BCAM CAR-T Cell(The First Affiliated Hospital of Nanchang University) ( BCMA )	复发性多发性骨髓瘤更多	早期临床1期
CG-102-12 ( GPC3 )	肝细胞癌更多	暂停